glycemic index carbohydrates. Over two months, low dose basal and bolus insulins were restarted due to intermittent hyperglycemia. On this insulin regimen and revised diet, there have been no further episodes of severe fasting hypoglycemia.
High fat and high calorie intake as well as the decline of physical activity leads to obesity, insulin resistance and more over metabolic syndrome, concomitant with increased visceral fat mass which is mainly caused by hypertrophy of adipocyte. Recently we have reported that by activating endogenous AMPK using 2, 4-dinitrophenol, release of monocyte chemoattractant protein-1(MCP-1) (a key inflammatory cytokine in insulin resistance) significantly decreases in mature 3T3-L1 adipocytes (BBRC 419:200-205, 2012) . However the molecular mechanism underlying this pathway is not completely understood. To elucidate the role of AMPK, in this study, we observed the effect of AMPK activation toward MCP-1 release and deposit of triglyceride in vitro model of artificially hypertrophied mature 3T3-L 1 adipocytes preloaded with palmitate. 3T3-L1 adipocytes were cultured with 300mmol/L palmitate for 24 h with or without pretreatment of AMPK activator [0.5mM AICAR (5-Aminomidazole-4-carboxamide ribonucleotide), 1mM AICAR, 25μM A-769662 or 2.5mM metformin]. Intracellular MCP-1 mRNA, protein, secretion of MCP-1, triglyceride contents and phosphorylated NFκB p65, ACC (Acetyl-CoA carboxylase) were quantified respectively. The cell showed hypertrophy by high palmitate with marked elevation of triglyceride, intracellular MCP-1 mRNA, protein, secretion of MCP-1 and phosphorylated NFκB. On the other hand, pretreatment of AMPK activators increased the phosphorylation of ACC, and then inhibited the palmitate induced elevation of not only the intracellular MCP-1 but also the phosphorylated NFκB. Interestingly, metformin showed the same effect as other AMPK activators.
In summary, our result demonstrated that activation of AMPK signaling decreases MCP-1 expression and the deposit of triglyceride in hypertrophied mature 3T3-L1 adipocytes. Increases in phosphorylated NFκB and ACC were considered to be, at least one part of the underlying molecular mechanisms.
2573-PUB Total Adiponectin and Adiponectin Multimeric Complexes Show Variable Associations with Metabolic Indices and Glycemic Status
NABILLA ABDELLA, OLUSEGUN A. MOJIMINIYI, Safat, Kuwait, Kuwait City, Kuwait Introduction: Adiponectin, a protective adipokine that increases insulin sensitivity (IS) and regulates glucose metabolism circulates in plasma as high (HMW), medium (MMW) and low molecular weight forms (LMW). Studies show the HMW form as the best indicator of IS. This study compares Total Adiponectin (TA) and the multimeric complexes according to their associations with metabolic and glycemic status.
Methods: Fasting TA, HMW, MMW, LMW, insulin, glucose, lipid profile and HbA1c were measured in 109 patients with type 2 diabetes (T2DM) and 112 nondiabetic first degree relatives. Clinical and anthropometric data were recorded. Subjects were classified by adiposity, insulin resistance (IR homeostasis model assessment) and the number of criteria of Metabolic Syndrome (MetS) (IDF criteria).
Results: TA (r = -0.21 and -0.24), HMW (r = -0.37 and -0.38) were significantly (p<0.05) inversely correlated with BMI and waist circumference respectively but MMW and LMW were not. TA (r = 0.23 and -0.24), HMW (r = 0.40 and -0.39) were significantly correlated with IS and IR respectively but MMW and LMW were not. Compared to HMW, Receiver Operating Characteristic (ROC) analysis showed that TA had the higher area under the curve for diagnoses of MetS (0.749 vs. 0.712) and T2DM (0.644 vs. 0.612) whereas HMW had the higher area under the ROC curve for diagnosis of IR (0.629 vs. 0.689).
Conclusions: Circulating TA and multimeric complexes show variable associations with metabolic indices and glycemic status. Our results suggest that MMW and LMW forms of adiponectin are not a major determinants of the metabolic perturbations of the adipokine. HMW is a better predictor of IR but TA is a better predictor of T2DM and MetS. As multimerisation is genetically determined, the predominant form of adiponectin could be the main determinant of the metabolic phenotype and disease associations. Multimeric forms should always be considered in the interpretation of the associations of circulating adiponectin.
Supported By: Kuwait Foundation for the Advancement of Science (2011 Science ( -1302 
2574-PUB Adipocytokines and Cardiometabolic Risk in a Biracial Cohort
IBIYE OWEI, DEIRDRE JAMES, NKIRU UMEKWE, SAMUEL DAGOGO-JACK, Memphis, TN Adipocytokines are associated with diabetes risk, but their link with cardiometabolic risk in diverse populations is unclear. We evaluated circulating adipocytokines in relation to adiposity, lipids, and glucoregulation in African Americans (AA) and European Americans (EA).
We studied 376 normoglycemic subjects (217 AA, 159 EA), all offspring of parents with type 2 diabetes. Each subject had clinical exam, OGTT, and lab tests including adipocytokines (hsCRP, TNF-α, IL-6, IL-1, resistin, and adiponectin). We also assessed insulin sensitivity (Si-clamp), beta-cell function, and body composition by dexa. Total Pro-inflammatory Cytokine Score (PCS) was derived as (hsCRP + TNF-α + IL-6 + IL-1 + resistin).
The mean (± SD) age of the subjects was 44.2 ± 10.6 yr; BMI 30.2 ± 7.2kg/ m2, fasting plasma glucose (FPG) 91.8 ± 6.8mg/dl and 2hr PG was 121.8 ± 24.4mg/dl. Adiponectin was lower (8.34 ± 4.95 μg/ml vs. 10.7 ± 5.44 μg/ml, P<0.0001), and hsCRP (4.67 ± 6.62 mg/L vs. 2.77 ± 4.55 mg/L, P=0.003) and PCS (25.4 ± 12.3 vs. 22 .51 ± 9.1, P=0.02) higher in AA vs. EA. Significant associations were seen between cardiometabolic measures (BMI, waist circumference, total and trunk fat, FPG, 2hrPG, HDL, triglycerides) and individual adipocytokines (P= 0.04 -< 0.0001), the strongest being with BMI (r=0.55 in AA, r=0.60 in EA, P< 0.0001). Individual and total pro-inflammatory cytokines were associated with insulin resistance, whereas adiponectin predicted greater insulin sensitivity (P=0.04 -<0.0001). Weaker and less consistent associations were noted between various adipocytokines and insulin secretion, the strongest being with adiponectin (r= -0.21, P=0.0002).
In conclusion, circulating adipocytokines display congruent relationships with adiposity, lipids, insulin sensitivity, and insulin secretion among normo- 
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glycemic black and white subjects. Total pro-inflammatory cytokine score was a better predictor of cardiometabolic risk than individual cytokines.
Supported By: American Diabetes Association Botanicals provide an important resource for drug development. Metformin, widely used in the treatment of type 2 diabetes, comes from French lilac. We have been studying various botanical extracts to identify potential antidiabetic properties. Our published studies indicate that an extract of Artemisia scoparia (SCOPA) has metabolically favorable effects on adipocyte development and function, both in vitro and in vivo. In diet-induced obese (DIO) mice, SCOPA supplementation (1% w/w in diet) reduced fasting glucose and insulin levels. In vitro, SCOPA enhanced adipogenesis as well as adiponectin expression and secretion from mature adipocytes. Given the responsiveness of adipocytes to SCOPA and the impact of circulating fatty acids on insulin resistance, we examined the effects of SCOPA on lipolysis in 3T3-L1 and human adipocytes. We observed that SCOPA produced a time-and dose-dependent inhibition of both basal and isoproterenol-stimulated lipolysis. In addition, SCOPA could inhibit TNFα-induced lipolysis and enhance the ability of insulin to inhibit lipolysis. These data are consistent with our unpublished observations that SCOPA supplementation in DIO mice reduced plasma levels of both free fatty acids and glycerol. Together, these data suggest an anti-lipolytic mechanism of SCOPA on adipose tissue to improve whole-body metabolic parameters, including improved insulin sensitivity and reduced circulating fatty acids. Obesity, and in particular abdominal obesity, is associated with insulin resistance, fatty liver disease, atherosclerosis and type 2 diabetes. Adipose tissue can expand by increasing fat cell size (hypertrophy) and/or fat cell number (hyperplasia). Increased fat cell size is associated with fat cell dysfunction and decreased adipose tissue density. Computed tomography (CT) is widely used for non-invasive quantification of abdominal subcutaneous fat (SF) and visceral fat (VF). However, CT can also be used to determine tissue densities. The aim of this study was to investigate how insulin affects adipose mass and density in diet-induced obese (DIO) diabetic rats. Streptozotozin-induced diabetic rats were treated with insulin (12, 18 or 24 nmol/rat/day) or vehicle for three weeks by constant infusion using osmotic mini-pumps. A nondiabetic group receiving vehicle was included as control. Endpoints were: glucose, HbA1c, body weight, whole body fat (WBF) and abdominal SF/VF mass/densities. Vehicle treated diabetic rats lost weight, WBF, SF and VF compared to nondiabetic controls. Furthermore, the SF/VF ratio decreased suggesting that primarily SF was lost whereas SF and VF densities increased suggesting smaller adipocytes in both tissues. Basal insulin replacement therapy reversed all the above mentioned parameters in a dose-dependent manner. The SF/VF ratio increased dose-dependently, further suggesting that insulin preferentially increases SF rather than VF. In both groups, the SF density was higher than the corresponding VF density. The results suggest that CT can be used to quantify SF and VF densities, which may act as surrogate markers of fat cell size, in rats, though the full potential of the method/parameter needs to be further explored. Background: Peroxisome proliferator-activated receptor gamma (PPARγ) is a key transcription factor regulating metabolism, inflammation and cell proliferation. PPARγ agonists are effective insulin sensitizers used in treating type 2 diabetes. Constitutive coactivator of PPARγ (CCPG) is a Fam120b gene encoding protein and is recognized as a novel constitutive coactivator of PPARγ. Being enriched in metabolic tissues, CCPG interacts with PPARγ and promotes adipogenesis. However, the potential role of CCPG in other tissues remains unclear. We hypothesize that CCPG is an important metabolic regulator in skeletal muscle cells.
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Methods and Results: We investigated the role of CCPG in cultured C2C12 myoblasts, with shRNA mediated stable CCPG knockdown (~70% decreased). Compared with the controlled C2C12 cell line with scrambled shRNA, CCPG knockdown prevented differentiation of C2C12 myoblasts into myotubes. Real time-PCR showed decreased transcript levels of myogenic regulatory factor MyoD and myosin heavy chain in CCPG knockdown compared to control C2C12 myoblasts. Myosin immune-staining confirmed the reduction of myotube from the C2C12 knockdown cells after the differentiation induction. Instead, lipid droplets were markedly increased. In addition, cellular energetic analysis using the Seahorse XF24 Bioanalyzer showed increased basal and maximal oxidative metabolism in CCPG knockdown C2C12 cells with consistent upregulation of glucose oxidation rates. Moreover, mtDNA copy number and PPARγ coactivator 1α (PGC-1α) mRNA and protein were increased in the CCPG knockdown C2C12 cells.
Conclusions: CCPG deficiency impairs C2C12 myoblast differentiation but instead facilitates the transdifferentiation into adipocytes, which accompanied by increased mitochondrial biogenesis and oxidative metabolism. Thus, we proposed that CCPG may play an important role in the differentiation of skeletal muscle cells and the trans-differentiation into adipocytes.
2578-PUB Mesenchymal Stem Cell Differentiation into Adipocytes Is Equally Induced by Insulin and Proinsulin In Vitro
ANDREAS PFÜTZNER, ANDREAS PANSKY, CLAUDIA KLEINFELD, BARBARA ROITZHEIM, EDDA TOBIASCH, Mainz, Germany, Rheinbach, Germany Background: In advanced β-cell dysfunction, proinsulin is increasingly replacing insulin as major component of the secretion product. It has been speculated that proinsulin has at least the same adipogenic potency than insulin, leading to an increased tendency of lipid tissue formation in patients with late stage β-cell dysfunction.
Methods: Mesenchymal stem cells obtained from liposuction material were grown in differentiation media containing insulin (0.01 μMol), proinsulin (0.01 μMol) or insulin+proinsulin (each 0.005 μMol). Cell culture supernatants were taken from these experiments and an untreated control at weeks 1, 2, and 3, and were stored at -80°C until analysis. Cell differentiation was microscopically supervised and adiponectin concentrations were measured as marker for differentiation into mature lipid cells. This experiment was repeated three times.
Results: No growth of lipid cells and no change in adiponectin values was observed in the negative control group (after 7/14/12 days: 3,2±0,5/3,3±0,1/4,4±0,5 ng/ml/12 h). A continuous differentiation into mature adipocytes (also confirmed by Red-Oil-staining) and a corresponding increase in adiponectin values was observed in the experiments with insulin (3,6±1,9/5,1±1,4/13,3±1,5 ng/ml/12 h; p<0.05 week 1 vs. week 3) and proinsulin (3,3±1,2/3,5±0,3/12,2±1,2 ng/ml/12; p<0,05). Comparable effects were seen with the insulin/proinsulin combination.
Conclusion: Proinsulin has the same adipogenic potential than insulin in vitro. Since the blood glucose lowering potency of proinsulin is much lower than that of insulin, much more PI needs to be secreted to control blood glucose in vivo. It can be speculated that the adipogenic potential of proinsulin may be a large contributor to the increased body weight problems in patients with type 2 diabetes and advanced β-cell dysfunction. 
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in vivo is largely unknown in part due to lack of a method for estimating sEH activity in vivo. Here, we propose such a method based on oxylipin analysis of plasma samples; sEH activity was estimated in conscious rats as the product to substrate ratio for each of 12-14 pairs of sEH substrates and products. This method showed a profound effect of a meal on sEH activity; sEH activity decreased ~70% 2.5 h after a meal in rats (P < 0.01). The decrease was significantly greater with a potassium-rich (2%) than with a potassium-deficient diet (74±2% vs. 65±3%, P < 0.05, n = 6 each), possibly explaining beneficial effects of dietary potassium on CV health. We next tested whether the postprandial inhibition of sEH was mediated by insulin action. For this, a hyperinsulinemic euglycemic clamp was performed for 2.5 h, and sEH activity was assessed before and after the clamp. sEH activity was not altered by the clamp (P > 0.05, n = 6), suggesting that insulin is unable to regulate sEH activity and cannot account for the postprandial inhibition of sEH. In summary, the present study demonstrates a profound decrease in sEH activity in postprandial states, which was enhanced by dietary potassium, and the postprandial decrease in sEH activity was not mediated by insulin. Elucidating the mechanism by which sEH is inhibited in postprandial states would help understand the role of this important enzyme in glucose homeostasis or CV health and may lead to new therapeutic strategies in the treatment of diabetes or CV diseases. Aim: In addition to its principal role in glucose homeostasis, insulin is a vasoactive hormone mediating endothelium-dependent vasodilation. In insulin resistant individuals the vasodilatory effect of insulin is impaired, which has been suggested to be a key phenomenon linking obesity, diabetes, and cardiovascular disease. In mice, diet-induced obesity has been shown to result in local insulin resistance in the vasculature. However, the effect of combined obesity and streptozotocin-induced diabetes on vascular insulin responsiveness has not previously been investigated.
Methods: Vasodilation and Akt phosphorylation induced by insulin and IGF-1 were investigated in mesenteric resistance arteries from mice fed low fat (lean) or high fat (dio) diet for 13 weeks and in dio mice treated with streptozotocin for the last 8 weeks of the high fat feeding period (stz-dio).
Results: Insulin and IGF-1 both induced endothelium-dependent vasodilation and Akt phosphorylation in mesenteric arteries from lean mice. IGF-1 (EC 50 0,26 nM) was a more potent vasodilator than insulin (EC 50 2,2 nM). Both vasodilation and Akt phosphorylation induced by insulin was impaired in arteries from dio mice compared to lean mice, whereas responses to IGF-1 were unaffected by diet-induced obesity. Insulin-induced vasodilation in stzdio mice was similar to lean mice.
Conclusions: Insulin and IGF-1 are vasodilators in mouse mesenteric arteries, and diet-induced obesity is associated with impaired insulin-induced vasodilation, whereas responses to IGF-1 are intact in dio animals. The impaired insulin-induced vasodilation seen in dio animals was rescued in stz-dio, suggesting hyperinsulinemia as a key driver of the vascular insulin resistance in dio mice. Cell, animal, and human evidence suggest that the breakdown of glucose homeostasis, characteristic of insulin resistance in obesity and type 2 diabetes (T2D), is secondary to cholesterol accumulation in skeletal muscle transverse tubule (T-tubule) membranes, which display high GLUT4-mediated glucose transport activity. Clinical data demonstrate that insulin resistance likely starts as early as 14 years before the onset of T2D. Moreover, transcriptome and epigenome data demonstrate that changes in cholesterol pathways predispose people to T2D. Whether skeletal muscle T-tubule membrane cholesterol accumulation could represent an early feature of insulin resistance remains unknown. To investigate, 6-wk old male C57BL/6 mice were fed either a low-fat (LF, 10% kcal) or high-fat (HF, 45% kcal) diet with adaptations regarding type of fat (palm oil instead of lard) and carbohydrates, to better mimic the average human diet in Western societies. While HF feeding for 1 wk did not result in a gain in body mass, these mice displayed elevated fasting glucose levels (24%, p=0.014). In addition, both glucose and insulin tolerance were impaired. Skeletal muscle T-tubule membrane cholesterol was increased by 41% (p=0.057) compared with that in LF-fed mice. A reciprocal loss of insulin-stimulated GLUT4 translocation was measured in these T-tubule membranes from HF-fed mice compared with that in LF-fed mice. Serum levels of tumor necrosis factor α and interleukin 6, markers of inflammation, were undetectable. High-density lipoprotein cholesterol levels were increased (18%, p=0.014), consistent with the possibility that reverse cholesterol transport was elevated to mitigate peripheral cell cholesterol accumulation. These data suggest skeletal muscle T-tubule membrane cholesterol accumulation to be an early etiological factor in T2D development, perhaps explaining the relationship between cholesterol metabolism gene networks and T2D. Prior experiments demonstrated that exposure to the common food additive carrageenan produced glucose intolerance and insulin resistance in C57BL/6J mice, due to activation of toll-like receptor-4 and reactive oxygen species-mediated inflammatory cascades and inhibition of insulin signaling by increased phospho (Serine308)-Insulin receptor substrate (IRS)-1. When C57BL/6J mice were exposed to carrageenan at a concentration of 10 mg/l in their water supply or to a high fat diet (HFD; 58%) for one year, carrageenan induced fasting hyperglycemia, and the combined effects of carrageenan and HFD on glucose tolerance and lipid parameters were more severe than HFD alone. Experiments were undertaken to identify the mechanisms accounting for the synergistic effects of carrageenan and high fat exposure. In the hepatic tissue of the mice, phospho (Ser307)-IRS1, an inhibitor of insulin signaling, increased to 2.7 times the control level following either carrageenan or HFD, and increased to 3.5 times baseline following combined exposure. In HepG cells, combined exposure to carrageenan (1 ug/ ml) and palmitate (20 uM x 24 h), increased phospho (Ser307)-IRS1 to over four times baseline, compared to increases of 3.0 times baseline from carrageenan and of 2.7 times following palmitate alone. Mitochondrial membrane potential was synergistically reduced, and parameters of lipid peroxidation, including malondialdehyde (MDA) and 4-hydroxyalkenals (HAE), were synergistically increased following carrageenan and high fat diet in the hepatic and pancreatic tissue of the mice. Planned experiments will further elucidate the underlying mechanisms for these synergistic effects. Carrageenan is consumed regularly in the Western diet at concentrations higher than the concentrations used in these experiments and may contribute to development of diabetes and atherosclerotic disease. Diabetes is one of the most common chronic metabolic diseases. In fact, the Center for Disease Control and Prevention estimated in 2014 that 9.3% of the United States population has diabetes. Simply put, diabetes is the body's inability to control glucose levels as a result of inadequate insulin production or because do not respond properly to insulin signaling. When blood glucose levels rise, however, a wide variety of problems arise and nearly every cell in the body can be affected. Among the most significant complications, diabetes is closely associated with cardiovascular disease. The advent of iPSC technology has raised the bar for current in vitro approaches to study diabetes by not only providing access to different human cell types from both normal and disease-affected individuals, but also enabling induced and innate disease models.
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Here we present a collection of data addressing how human iPSC-derived cell types (including cardiomyocytes -CM, hepatocytes -HC, and skeletal muscle -SkM) have been used for diabetes investigation. Examples include dissecting the cell signaling events following insulin stimulation (e.g., phospho-AKT and glucose uptake) in CM and SkM, modulating gluconeogenesis in HC with cells in both 2D and 3D spheroid cell culture (e.g., measuring glucose output), and modeling diabetic cardiomyopathy in CM cultured under stress-inducing conditions (e.g,. cardiac activity and calcium oscillations affected by diabetic medium).
Together, these examples showcase how iPSC-derived cell types can be further utilized to analyze the molecular mechanisms responsible for pathophysiology of diabetic disorders (e.g., insulin resistance). Additionally, 
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establishment of a disease model with a testable disease phenotype has the potential to be implemented for use in drug screening.
2584-PUB Novel Routes for PTP1B Drug Design: Leveraging Dynamic Allostery
WOLFGANG PETI, Tucson, AZ
Over the last years, multiple efforts have been undertaken in order to understand how the synergy of structural rigidity, dynamics at different timescales and conformational and/or dynamic allostery ultimately allows for enzyme function. In spite of these efforts, no one has so far succeeded. Here, I will describe how we have closed this gap of missing fundamental knowledge by demonstrating how conformational rigidity, dynamics and allostery are combined to control the activity of Protein Tyrosine Phosphatase 1B (PTP1B, ~40 kDa), a well-established drug target for obesity and especially diabetes. We achieved this by integrating a wealth of techniques, including NMR spectroscopy (6 variants -full assignment; NMR relaxation data), X-ray crystallography (16 structures), extensive biochemistry/enzymology (13 variants; different inhibitor complexes, among others) and finally, cutting-edge NMR-restrained molecular dynamics (MD) simulations. This unrivaled comprehensive approach revealed that PTP1B activity is regulated by a conformational rigidity that functions as ratchet to propel the loop motions on a μs timescale necessary for hydrolysis. In parallel, allosterically mediated, entropically driven fast timescale (ps-ns) events stabilizes these clockwork type movements to fine-tune PTP1B regulation. Remarkably, modulation of these events is used in vivo to regulate the activity of PTP1B. These discoveries not only answer fundamental questions about the properties that control enzyme function, but are now being be used for the development of novel compounds that target not only structural features of PTP1B, but also target their dynamics to inhibit PTP1B function, effort that will lead to entirely novel classes of chemical probes and drugs for the treatment of diabetes. The insulin receptor is expressed in the intestine and insulin in the bloodstream is able to activate these receptors. Since the bioavailability of orally administered insulin is low, it could be hypothesized that the unabsorbed insulin may induce a local effect in the intestine different to that of parenteral insulin treatment. The aim of this study was to compare the acute effect on insulin-stimulated intracellular signalling in the small intestine in rats after insulin administration either by intraintestinal (II) injection or IV infusion. For this comparison, algorithms for IV infusion of insulin in rats were developed to precisely match the PK-and PD-properties of insulin administered by II injection in the mid-jejunum, which was used as a model of orally administered insulin. Rats were then treated with insulin by II injection or IV infusion and euthanized after 5 min to collect samples of the liver and jejunum. Levels of phosphorylated Akt (ser473) were then assessed in the tissue samples, and used as biomarker of insulin-stimulated intracellular signalling. Treatment with insulin by both administration routes resulted in significant activation of Akt in the liver when compared to vehicle-treated rats. Insulin treatment also resulted in significant activation of Akt locally in the intestine with no significant difference observed between rats treated with insulin by II injection or IV infusion.
In conclusion, insulin treatment by II injection or IV infusion to matched PK-and PD-effects resulted in comparable activation of Akt in the intestine. The results from this rat model of orally administered insulin therefore suggest that the unabsorbed insulin found in the intestinal lumen after oral administration will not result in an enhanced acute effect in the intestine.
2586-PUB Insulin and IGF-1 Receptor Distribution in the Murine Gastrointestinal Tract
BORJA BALLARIN-GONZALEZ, JONAS AHNFELT-RØNNE, HENNING HVID, BO F. HANSEN, ERICA NISHIMURA, Måløv, Denmark Liver, adipose tissue and skeletal muscle are traditionally considered main targets of insulin action. However, it is becoming evident that insulin may also regulate physiological processes in other organs, including the gastrointestinal tract.
In the present study we have investigated the expression and distribution of insulin and IGF-1 receptors (InsR and IGF-1R, respectively) in the gastrointestinal tract of mice and rats.
Western blot analysis demonstrated relatively low levels of both receptors in the duodenum, jejunum and ileum of the animals, with receptor expression gradually increasing from the proximal to the more distal regions of the small intestine. Maximal receptor levels were observed in the ascending and transversal sections of the colon which, normalised to tissue weight, expressed approximately 50-75% of the InsRs found in liver tissue. qPCR analysis of rat intestinal tissue confirmed the described receptor distribution and supported the observations from the Western blot analyses suggesting an on par or higher levels of InsR compared to IGF-1R for most of the intestinal regions.
Immunohistochemical (IHC) analyses of mouse and rat duodenum, jejunum and colon samples using validated antibodies demonstrated a homogeneous distribution of insulin receptors along the crypt-villus axis, while IGF-1 receptors predominantly localised to the crypt regions. Furthermore, phosphorylation of Akt, an effector molecule downstream of the InsR, was detected in duodenum, jejunum and colon samples of animals treated with a subcutaneous injection of human insulin (HI), but not in control animals treated with vehicle, suggesting that the receptors in the intestinal tract are activated by insulin circulating in the blood stream.
Although gut specific functions of insulin have not been fully elucidated yet, our results demonstrating high InsR expression in various regions of the gastrointestinal tract, suggest an important role of insulin in this organ system.
2587-PUB Assessment of Insulin Sensitivity from an OGTT with Different Glucose Loads, and Under the Presence of Urinary Glucose Excretion in Rats
MASAFUMI MATSUDA, MACHIKO NISHIJIMA, Kawagoe, Japan While several insulin sensitivity indices are available from an oral glucose tolerance test (OGTT), there has been no validation of their applicability when an amount of glucose load is different, or glucose is excreted from the urine. In the latter case, the effect of insulin appears greater as more glucose is cleared. Therefore it is necessary to modify the calculation including an administered dose of glucose or excreted glucose in the urine during an OGTT. To assess the validity of the correction methods, we conducted an OGTT giving different doses (0.5(n=2), 1(n=3), 2(n=4) g/kg BW, 120 min) of glucose and phlorizin (300mg/kg propylene glycol 1mL i.p., oral glucose 1 g/ kg (n=3)) in male Wistar rats (~200g, from Japan SLC). We also conducted a euglycemic insulin clamp (10mU/kg per min, 90 min) with 3-3 H-glucose infusion in the same rats within a week after the OGTT. Matsuda index (MI, Diabetes Care 22:1462) was corrected by the square root of the ratio of amount of glucose loaded. OGIS (Diabetes Care 24:539) was corrected by the ratio of amount of glucose loaded in the parameter 1, being other parameters same as humans. The corrected indices and the rate of disappearance of glucose (Rd) during the clamp was compared. Without phlorizin, MI, OGIS, HOMA%S, and Rd were 108±89, 7618±3419, 404±326 and 70±50mg/kg per min respectively. Corrected MI and OGIS were 107±62 and 6427±1194 with less variability. With phlorizin, MI, OGIS, and Rd (same rat without phlorizin) were 135±82, 8282±925 and 62±25mg/kg per min. Corrected MI and OGIS were 72±26 and 4244±864. When all values were included, the correlation coefficient of MI and OGIS to Rd were improved from 0.68 to 0.88, and from 0.70 to 0.74. Although the use of a euglycemic insulin clamp should be the choice, theoretical correction may improve the accuracy of insulin sensitivity indices. The evaluation of insulin sensitivity in hyperglycemic condition and under the use of a SGLT2 inhibitor should be carefully appreciated. This study investigated the effects of Tetrapanax papyrifer extract (TPE) in a mouse model of diabetes (C57BL/KsJ db/db). Four treatment groups received diabetic control group (DC), 100 or 200 mg/kg TPE (TPE 100 or PCE 200), or 10 mg/kg pinitol (pinitol 10) daily for 8 weeks. Fasting blood glucose levels were 59% lower in TPE 200 mice and 43% lower in the pinitol 10 group. Insulin levels were 1.3-fold higher in the TPE 200 group, than in the DC. Furthermore, the PCE 100 mice showed 1.5-fold increased C-peptide and adiponectin levels and 23% decreased HbA1c levels. Compared to the DC mice, the PCE-treated mice showed significant prevention of pancreatic β-cell damage and higher insulin content in immunohistochemical analyses. To investigate TPE's mechanism of action, microarray analyses were performed liver and fat tissues.
In summary, our results suggested that TPE exerted antidiabetic effects through protection of pancreatic β-cells, increase of insulin secretion, and reduction of blood glucose level by improving insulin sensitivity in C57BL/ KsJ db/db mice. We aimed to investigate the effect of glycemic control on beta cell function, insulin sensitivity, and disposition function during long-term CSII therapy (for up to 2 years) in patients with type 2 diabetes (T2D). We discontinued oral antidiabetics and applied CSII therapy to T2D patients (number, 570 with 54.1% of male; age, 59.5 ± 9.8 years; duration, 11.6 ± 8.1 years; HbA1c 9.0 ± 2.0%; BMI 24.3 ± 3.4 kg/m 2 ). Blood samplings were performed at 6 month and yearly, after overnight fasting and 120 minutes after ingestion of a standard mixed meal (500 kcal). Serum C-peptide, glucose, and HbA1c were measured, and C-peptidogenic Index (CI), Matsuda Index (MI), and disposition Index (DI) were calculated. Patients were divided into Good (G; n=194, HbA1c ≤ 6.5%), Medium (M; n=271, 6.5% <HbA1c ≤ 7.5%), and Poor (P; n=105, HbA1c >7.5%) glycemic control groups by the mean value of HbA1c during 2 years of CSII therapy: the effects of glycemic control on serum C-peptide were different among these groups (Figure) , i.e., the lower the HbA1c, the higher the serum C-peptide.
In conclusion, the capacity of controlling hyperglycemia (serum C-peptide, CI, MI, and DI) in T2D might be affected by the degree of glucotoxicity during CSII therapy. 
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Protective Biphasic Insulin Secretion with Decreasing Circulating Free Fatty Acid Level in Newly Diagnosis T2DM SHARVAN RAMPERSAD, Shanghai, China A biphasic insulin secretion during the 5-point Oral Glucose Tolerance Test is not an expected and normal finding. We wanted to know what kind of patients have such finding, and what phenotypes of these patients differ from other controls. We collected data about patients having a biphasic insulin secretion and compared them to both normal healthy subjects and to diabetic patients with absence of the first insulin secretory phase. Only male patients between 30 to 55 years of age, having a similar BMI, were selected for this comparison. The 3 groups were divided into group 1 having only normal controls, group 2 comprising of those with a biphasic insulin secretion and group 3 consisting of type 2 diabetes mellitus (T2DM) patients with a delayed insulin secretion. Most patients in the biphasic group were newly diagnosed type 2 diabetic patients, with a glucometabolic profile in between the other 2 groups. Hence, these were shown to represent the early stage of T2DM pathogenesis. Of interest, they had the lowest free fatty acid (FFA) levels (0.55±0.18 vs. 0.29±0.14 vs. 0.48±0.21, P-values being 0.001 and 0.009 respectively) while the other parameters of the lipid profile were not significantly different. We believe this decreased in FFA level to be due to a protective mechanism in order to decrease insulin resistance in the skeletal muscle by decreasing competition between glucose and FFA for energy production. This is most probably due to the diacylglycerol O-acyltransferase 2 (DGAT2) enzyme activity. Hence, found that presence of a biphasic insulin secretion indicates early pathogenesis of T2DM. Moreover, a FFA lowering mechanism, we believe to halt the progress of peripheral insulin resistance, probably by an increase in DGAT2 activity, exists. Intravenous glucose (ivGTT) and mixed meal tolerance tests (MMTT) are commonly used to evaluate glucose homeostasis in both human and laboratory animals. Spontaneously developed diabetes in non-human primates (NHPs), as a translatable model for assessing antidiabetic therapeutics, have been shown to exhibit abnormal glucose control similar to that in type 2 diabetic (T2D) patients. However, the effects of anesthesia on glucose or hormonal responses during these tests are not known. The aim of this study is to further characterize the metabolic responses of glucose and hormonal changes during ivGTT and MMTT in the presence or absence of anesthesia.
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